drugset / Trial / NCT01213394

Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients

NCT01213394

Phase 3 Terminated 2 enrolled Ramesh Prasad Hoffmann-La Roche · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this research study is to determine if adding or increasing the dose of CellCept while lowering the dose of tacrolimus (Prograf or Advagraf) or cyclosporine (Neoral), and/or steroids can reduce the likelihood of developing coronary heart disease in the next 10 years. The investigators will calculate the change in risk of developing coronary heart disease using the Framingham score. The Framingham score is a mathematical equation that includes the following information: Age, Gender, Diabetes status, Smoking status, Lipids, Blood Pressure. The Framingham score estimates how likely it is that someone will develop coronary heart disease over the next 10 years.

Timeline

Start
2010-10
Primary completion
2011-10
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 2 g